15,000 Moderna, Inc. $MRNA Shares Sold by Quattro Financial Advisors LLC

Quattro Financial Advisors LLC decreased its holdings in Moderna, Inc. (NASDAQ:MRNA) by 60.0% during the third quarter, HoldingsChannel.com reports. The firm owned 10,000 shares of the company’s stock after selling 15,000 shares during the quarter. Quattro Financial Advisors LLC’s holdings in Moderna were worth $1,926,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. NFSG Corp lifted its holdings in Moderna by 2,581.0% during the 3rd quarter. NFSG Corp now owns 5,362 shares of the company’s stock valued at $1,033,000 after buying an additional 5,162 shares in the last quarter. R2 Capital Strategies LLC purchased a new position in shares of Moderna during the third quarter worth approximately $347,000. Cohen Klingenstein LLC purchased a new position in shares of Moderna during the third quarter worth approximately $404,000. PFG Private Wealth Management LLC purchased a new position in shares of Moderna during the third quarter worth approximately $473,000. Finally, State of Alaska Department of Revenue raised its stake in shares of Moderna by 1.7% during the third quarter. State of Alaska Department of Revenue now owns 35,174 shares of the company’s stock valued at $6,773,000 after acquiring an additional 573 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Trading Up 4.5%

NASDAQ MRNA opened at $236.50 on Friday. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The firm has a market cap of $94.42 billion, a PE ratio of -29.60 and a beta of 1.09. The company has a 50 day moving average price of $153.48 and a 200 day moving average price of $89.98. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $242.29.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. The company had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. Moderna’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($2.13) earnings per share. As a group, sell-side analysts forecast that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 34,836 shares of Moderna stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the sale, the chief financial officer owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. The trade was a 36.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the transaction, the insider owned 74,129 shares in the company, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 118,882 shares of company stock worth $16,862,280 in the last three months. Corporate insiders own 10.80% of the company’s stock.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Investor enthusiasm is building ahead of data from Moderna and Merck’s personalized melanoma vaccine program. The companies’ mRNA cancer-vaccine partnership is the primary catalyst behind the recent surge, with investors hoping clinical results could validate a major new growth market. Moderna outweighs bearish views ahead of cancer vaccine data
• Positive Sentiment: Merck’s chief executive said the companies expect manufacturing of their cancer vaccine to become faster over time. He described the production process as complex but increasingly well controlled, addressing an important potential commercialization concern. Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
• Positive Sentiment: Goldman Sachs raised its Moderna price target to $137 from $120 while retaining a Neutral rating. Although the target remains well below the current trading level, the increase reflects improved expectations ahead of the melanoma data. MRNA Stock Hits Fresh 52-Week Highs As Goldman Raises Target Ahead Of Melanoma Data
• Positive Sentiment: Money has rotated into healthcare and away from crowded technology trades, providing an additional momentum tailwind for Moderna and other biotechnology stocks. Moderna Rallies as Money Rotates Into Healthcare
• Neutral Sentiment: Moderna’s flu-vaccine opportunity remains prospective; coverage on where consumers can obtain an mRNA flu shot highlights that such products are not yet broadly available, limiting any immediate revenue impact. Where Can I Get an mRNA Flu Shot?
• Negative Sentiment: Analysts and commentators warn that the stock’s dramatic year-to-date rebound has outpaced fundamentals. Moderna remains unprofitable, generates negative free cash flow, and is highly dependent on successful pipeline execution. Q3 results on November 6 and Analyst Day on November 12 could produce substantial volatility. Moderna Valuation Is Uncertain
• Negative Sentiment: Goldman’s $137 target implies roughly 42% downside from the quoted share price, underscoring the risk that expectations for cancer-vaccine data may already be heavily reflected in Moderna’s valuation. Moderna Stock Is Soaring on Cancer Vaccine Buzz

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Moderna in a report on Wednesday, September 9th. CLSA raised shares of Moderna to an “outperform” rating in a report on Friday, August 28th. Morgan Stanley lifted their price objective on shares of Moderna from $89.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. Citigroup downgraded shares of Moderna from a “neutral” rating to a “sell” rating and boosted their price objective for the stock from $60.00 to $80.00 in a research note on Wednesday, September 30th. Finally, William Blair initiated coverage on Moderna in a report on Friday, August 28th. They set an “outperform” rating for the company. Seven investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, Moderna presently has a consensus rating of “Hold” and an average price target of $101.45.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.